A clinical-stage biotechnology company focused on developing small‑molecule inhibitors targeting focal adhesion kinase (FAK) for the treatment of cancer and fibrotic diseases. Its lead drug candidates are being studied in clinical trials, including combinations aimed at improving outcomes in pancrea...
2 members of Congress have disclosed 2 trades in Amplia Therapeutics Limited (INNMF), a Healthcare company. The buy/sell breakdown shows 2 purchases versus 0 sales, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2017-04-21 | Jared Polis | buy | $50K – $100K |
| 2010-04-02 | JAMES B. RENACCI | buy | $741.95 |